CorestemChemon's Neuronata-R Advances toward ALS Stem Cell Market in Korea and the U.S. CorestemChemon is making significant strides in ALS stem cell therapy with Neuronata-R, focusing on regulatory processes in Korea and expanding into the U.S. market.

CorestemChemon's Neuronata-R Advances toward ALS Stem Cell Market in Korea and the U.S. #South_Korea #Seoul #Neuronata-R #CorestemChemon #ALS_Therapies

ALS Association Invests $2 Million in Innovative ALS Therapies Through Clinical Trials The ALS Association announces a significant $2 million investment into early-stage clinical trials for two promising ALS therapies, aiming to expedite treatment development.

ALS Association Invests $2 Million in Innovative ALS Therapies Through Clinical Trials #United_States #Arlington #Clinical_Trials #ALS_Association #ALS_Therapies